Clinical Evidence

Our clinical programs are leading the field

Explore the scientific evidence supporting GRAIL’s multi-cancer early detection approach, including peer-reviewed publications and presentations at leading medical congresses. Together, these data highlight test performance, clinical utility, and progress toward transforming cancer screening.

Jump to:

MANUSCRIPTS

PRESENTATIONS

Foundational data

Validation
CCGA

Case-control study

Annals of Oncology

Read Full Article
Clinical Performance
PATHFINDER 2

Prospective screening study

Nature Medicine

Read Full Article
Clinical Utility
NHS-Galleri

Randomized control study

Nature Medicine

Read Full Article
Performance in Medicare
Real-World Experience

Prospective real-world study

Nature Communications

Read Full Article

Featured evidence

Presentation

European Society for Medical 
Oncology (ESMO) 2025

Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study

See Presentation
Manuscript

JCO Precision Oncology

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes of Analysis

Read Full Article
Manuscript

Cancer Prevention Research

Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches

Read Full Article
Presentation

American Association of Cancer Research (AACR) 2026

Association Between Emergency Department (ED) Involvement in Cancer Diagnosis and Survival Across Cancer Types in the Medicare Population

See Presentation

Manuscripts

Cancer Prevention Research

Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches

May 8, 2026
View Manuscript
British Journal of Cancer

Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England

April 24, 2026
View Manuscript
Cancer

Early cancer detection in a large American Cancer Society cohort study: Retrospective analysis of methylated DNA biomarkers

April 12, 2026
View Manuscript
Cancer

Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3

April 9, 2026
View Manuscript
JCO Precision Oncology

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis

March 12, 2026
View Manuscript
JCO Precision Oncology

Prevalence of BRCA1 Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA

March 9, 2026
View Manuscript